Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ev-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer

  • Roman-Canal, Berta|||0000-0002-6784-0077
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Gatius, Sònia
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Ruiz-Miró, María
  • González, Esperanza
  • González-Tallada, Xavier
  • Llordella, Ivanna
  • Hernández, Isabel|||0000-0001-8119-393X
  • Porcel, José M.|||0000-0002-2734-8061
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Ponomarenko, Julia|||0000-0002-1477-9444
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and is responsible for more than 89,000 deaths every year. Mortality is associated with presence of poor prognostic factors at diagnosis, i.e., diagnosis at an advanced stage, with a high grade and/or an aggressive histology. Development of novel approaches that would permit us to improve the clinical management of EC patients is an unmet need. In this study, we investigate a novel approach to identify highly sensitive and specific biomarkers of EC using extracellular vesicles (EVs) isolated from the peritoneal lavage of EC patients. EVs of peritoneal lavages of 25 EC patients were isolated and their miRNA content was compared with miRNAs of EVs isolated from the ascitic fluid of 25 control patients. Expression of the EV-associated miRNAs was measured using the Taqman OpenArray technology that allowed us to detect 371 miRNAs. The analysis showed that 114 miRNAs were significantly dysregulated in EC patients, among which eight miRNAs, miRNA-383-5p, miRNA-10b-5p, miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and miRNA-34b-3p, demonstrated a classification performance at area under the receiver operating characteristic curve (AUC) values above 0.9. This finding opens an avenue for the use of EV-associated miRNAs of peritoneal lavages as an untapped source of biomarkers for EC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta|||0000-0002-6784-0077
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Gatius, Sònia
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Ruiz-Miró, María
  • González, Esperanza
  • Ojanguren, Amaia
  • Recuero, José Luis
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Ponomarenko, Julia|||0000-0002-1477-9444
  • Porcel, José M.|||0000-0002-2734-8061
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer

  • Parrilla, Alfonso
  • Barber, Marta
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Castellvi, Josep|||0000-0001-5745-9996
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Sánchez Iglesias, José Luis|||0000-0002-4542-3969
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic protein that plays a key role in activating the master mitotic kinase polo-like kinase 1 (PLK1), has an oncogenic role in ovarian cancer. Gain and loss of function assays on mouse models and ex vivo patient-derived ascites cultures revealed an oncogenic role of BORA in tumor development and a transcriptome-analysis in clinically representative models depicted BORA's role in survival, dissemination and inflammatory cancer related-pathways. Importantly, combinatory treatments of FDA-approved inhibitors against oncogenic downstream effectors of BORA displayed synergistic effect in ovarian cancer models, offering promising therapeutic value. Altogether, our findings uncovered for the first time a critical role of BORA in the viability of human cancer cells providing potential novel therapeutic opportunities for ovarian cancer management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients, A Mini-Review

  • Bradbury, Melissa|||0000-0003-4974-8899
  • Borràs, Eva|||0000-0002-3859-9907
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Sabidó, Eduard|||0000-0001-6506-7714
In this manuscript, we review the management strategies available for high-grade serous ovarian cancer patients and the molecular advances that are helping improve our understanding of the tumor and its response to treatment. We emphasize the role that proteomics is now playing in the study of ovarian cancer tumors and how its integration with genomics can guide the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury, Melissa|||0000-0003-4974-8899
  • Castellvi, Josep|||0000-0001-5745-9996
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Sánchez Iglesias, José Luis|||0000-0002-4542-3969
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Borràs, Eva|||0000-0002-3859-9907
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool

  • Villafranca-Magdalena, Beatriz|||0000-0001-9921-919X
  • Masferrer-Ferragutcasas, Carina|||0000-0002-4561-1820
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Rebull, Marta
  • Parra, Genis
  • García, Ángel
  • Reques, Armando|||0000-0002-7197-9354
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
Endometrial cancer (EC) is the second most frequent gynecological cancer worldwide. Although improvements in EC classification have enabled an accurate establishment of disease prognosis, women with a high-risk or recurrent EC face a dramatic situation due to limited further treatment options. Therefore, new strategies that closely mimic the disease are required to maximize drug development success. Patient-derived xenografts (PDXs) are widely recognized as a physiologically relevant preclinical model. Hence, we propose to molecularly and histologically validate EC PDX models. To reveal the molecular landscape of PDXs generated from 13 EC patients, we performed histological characterization and whole-exome sequencing analysis of tumor samples. We assessed the similarity between PDXs and their corresponding patient's tumor and, additionally, to an extended cohort of EC patients obtained from The Cancer Genome Atlas (TCGA). Finally, we performed functional enrichment analysis to reveal differences in molecular pathway activation in PDX models. We demonstrated that the PDX models had a well-defined and differentiated molecular profile that matched the genomic profile described by the TCGA for each EC subtype. Thus, we validated EC PDX's potential to reliably recapitulate the majority of histologic and molecular EC features. This work highlights the importance of a thorough characterization of preclinical models for the improvement of the success rate of drug-screening assays for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer

  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Martinez-Garcia, Elena|||0000-0003-2547-7916
  • Dittmar, Gunnar|||0000-0003-3647-8623
  • Nazarov, Petr V.
  • Bebia, Vicente|||0000-0001-6434-2112
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) mortality is directly associated with the presence of poor prognostic factors. Molecular prognostic factors have been identified, but none are used in clinical practice due to lack of validation studies. This study aims to validate a set of 255 prognostic biomarkers previously identified in an extensive literature review and explore new prognostic applications by analyzing them in The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases. A total of 30 biomarkers were validated and associated to a histological type (n = 15), histological grade (n = 6), FIGO stage (n = 1), molecular classification (n = 16), overall survival (n = 11), and recurrence-free survival (n = 5). Our results encourage further studies of understudied biomarkers such as TPX2, and validates already broadly studied biomarkers such as MSH6, MSH2, or L1CAM, among others. Finally, our results present a significant step to advance the quest for biomarkers to accurately assess the risk of EC patients. Endometrial cancer (EC) mortality is directly associated with the presence of prognostic factors. Current stratification systems are not accurate enough to predict the outcome of patients. Therefore, identifying more accurate prognostic EC biomarkers is crucial. We aimed to validate 255 prognostic biomarkers identified in multiple studies and explore their prognostic application by analyzing them in TCGA and CPTAC datasets. We analyzed the mRNA and proteomic expression data to assess the statistical prognostic performance of the 255 proteins. Significant biomarkers related to overall survival (OS) and recurrence-free survival (RFS) were combined and signatures generated. A total of 30 biomarkers were associated either to one or more of the following prognostic factors: histological type (n = 15), histological grade (n = 6), FIGO stage (n = 1), molecular classification (n = 16), or they were associated to OS (n = 11), and RFS (n = 5). A prognostic signature composed of 11 proteins increased the accuracy to predict OS (AUC = 0.827). The study validates and identifies new potential applications of 30 proteins as prognostic biomarkers and suggests to further study under-studied biomarkers such as TPX2, and confirms already used biomarkers such as MSH6, MSH2, or L1CAM. These results are expected to advance the quest for biomarkers to accurately assess the risk of EC patients.